Cover Image

High-dose therapy and autologous stem cell transplantation for extra-nodal NK/T lymphoma in patients from the Western hemisphere: a study from the European Society for Blood and Marrow Transplantation

Extra-nodal NK/T lymphoma (ENKTL) is rare and more frequently encountered in East Asia. The role of high-dose therapy and autologous stem cell transplantation (HDT-ASCT) for ENKTL is unclear. Twenty-eight evaluable patients who had undergone HDT-ASCT in Europe from 2000-2009 were studied. The median...

Full description

Saved in:
Bibliographic Details
Main Authors: Fox, Christopher (Author) , Dreger, Peter (Author)
Format: Article (Journal)
Language:English
Published: 26 Aug 2015
In: Leukemia and lymphoma
Year: 2015, Volume: 56, Issue: 12, Pages: 3295-3300
ISSN:1029-2403
DOI:10.3109/10428194.2015.1037764
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3109/10428194.2015.1037764
Get full text
Author Notes:Christopher P. Fox, Ariane Boumendil, Norbert Schmitz, Herve Finel, Jian J. Luan, Gülsan Sucak, Didier Blaise, Jürgen Finke, Karl-Heinz Pflüger, Hendrik Veelken, Norbert -Claude Gorin, Xavier Poiré, Arnold Ganser, Peter Dreger, Anna Sureda
Description
Summary:Extra-nodal NK/T lymphoma (ENKTL) is rare and more frequently encountered in East Asia. The role of high-dose therapy and autologous stem cell transplantation (HDT-ASCT) for ENKTL is unclear. Twenty-eight evaluable patients who had undergone HDT-ASCT in Europe from 2000-2009 were studied. The median age was 47 years and patients had received a median of two lines of prior therapy. Some 57% of patients were not in complete remission or beyond first complete remission at HDT-ASCT. The 1-year non-relapse mortality (NRM) was 11%; 2-year progression-free survival (PFS) and overall survival (OS) rates were 41% and 52%, respectively. Notably, the 2-year PFS and OS for those with stage III/IV disease were 33% and 40%, respectively, with no relapses beyond 1-year post-HDT-ASCT. This is the largest analysis of HDT-ASCT for patients with ENKTL reported from the Western hemisphere. Survival is comparable to East Asian cohorts and outcomes are encouraging for patients with advanced disease.
Item Description:Gesehen am 05.08.2021
Physical Description:Online Resource
ISSN:1029-2403
DOI:10.3109/10428194.2015.1037764

Similar Items